Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01609283 · ClinicalTrials.gov registry record · Phase 1
A Dose-escalation Safety Trial for Intrathecal Autologous Mesenchymal Stem Cell Therapy in Amyotrophic Lateral Sclerosis
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT01609283: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT01609283 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 27 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01609283, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The purpose of this study is to determine determine the safety of intraspinal delivery of mesenchymal stem cells (MSCs) to the cerebral spinal fluid of patients with Amyotrophic Lateral Sclerosis (ALS) using a dose-escalation study.
Interventions
- BIOLOGICAL autologous mesenchymal stem cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2012-05 |
| Est. Completion | 2019-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01609283
The ClinicalTrials.gov registry entry for NCT01609283 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which autologous mesenchymal stem cells is the first listed.
NCT01609283 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01609283 about?
NCT01609283 is a clinical study titled "A Dose-escalation Safety Trial for Intrathecal Autologous Mesenchymal Stem Cell Therapy in Amyotrophic Lateral Sclerosis". The purpose of this study is to determine determine the safety of intraspinal delivery of mesenchymal stem cells (MSCs) to the cerebral spinal fluid of patients with Amyotrophic Lateral Sclerosis (ALS) using a dose-escalation study.
What is the current status of trial NCT01609283?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2012-05. Estimated completion is 2019-01-31.
What interventions are being tested in trial NCT01609283?
The interventions under investigation include: autologous mesenchymal stem cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT01609283?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.